SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

CAW CRYPTO is trending due to strong community support and its growing presence across multiple blockchains. The community emphasizes its organic growth, deflationary mechanisms, and growing partnerships, rallying behind the "crow with knife" meme.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending due to speculation around potential U.S. government investment in its Greenland rare earths mine, with community members citing a Reuters report and comparing it to similar situations with $LAC. Community discussion revolves around the potential for a significant price increase, the company's ownership structure, and the upcoming BFS (Bankable Feasibility Study). Some traders express bullish sentiment and anticipate substantial gains, while others caution against potential volatility and profit-taking.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as the community anticipates the sunsetting of $PRQ, which some believe has been holding REACT back. Community members express excitement about the project's potential, integrations, and staking rewards, while also speculating on future exchange listings. Some suggest that Reactive Network could be a hidden gem with significant long-term growth potential, especially in the realm of cross-chain automation.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders assess its recent parabolic move, with community members pointing to overbought RSI levels and a potential double top, suggesting a possible retracement. Despite robust performance and recent buyouts in the biotech sector, some investors are hedging with inverse ETFs, while others anticipate a pullback to fill gaps, as well as a cool off from an overbought market.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential integrations and real-world asset (RWA) applications. Conversations revolve around potential partnerships, particularly with $SUI and $WLFI, alongside speculation about future revenue and tokenomics. Some users are also anticipating a broader altcoin season, contingent on $BTC dominance declining.

RiverNorth/DoubleLine Strategic opportunity fund Inc

OPP is trending due to the recent completion of its rights offering, with the community actively discussing its potential impact on share dilution and NAV. Some investors are weighing the pros and cons of participating in the offering, while others are evaluating the newly issued preferred shares. The fund's high yield characteristics and sensitivity to interest rates remain a key focus for discussion.

About Cartesi (CTSI)  Cartesi enables developers to build appchain rollups with any code, while benefiting from the security of Ethereum. It bridges the gap between traditional software and blockchain by bringing decades of mature operating systems, programming languages, libraries, and tools to decentralized applications.  Cartesi aims to provide the technological foundation from which builders, entrepreneurs, and projects will develop decentralized applications. The Cartesi technology suite is currently comprised of:  Cartesi Rollups: Cartesi Rollups is an app-specific execution environment that can be deployed as a L2, L3, or as sovereign rollups. The combination of an Optimistic Rollups framework and the Cartesi Machine Emulator enables the development of smart contracts and dApps using any package or library that is available for Linux. This allows developers to break free from the scalability limitations of the Ethereum Virtual Machine (EVM), and brings the rise of a new blockchain era to handle real-life and complex use cases.  Cartesi Machine: A RISC-V-based virtual machine (altVM) running Linux OS, enabling complex computations and seamless dApp development by expanding the design space and leveraging 40 years of software programming advancements.  CartesiScan: Cartesiscan is the explorer used for viewing blockchain transactions on Cartesi appchain rollups.  Cartesi Explorer: The Cartesi Explorer is a product that allows CTSI users to interact with the governance system and stake CTSI.  Fraud Proof System - DAVE (following PRT): Dave is a permissionless, interactive fraud-proof system. Cartesi’s algorithm further optimizes the fraud proof mechanism to achieve the best balance between security, decentralization, and activity.  What Makes Cartesi Unique  The infrastructure of the internet took 40 years, billions of hours of work, and trillions of dollars to build. With Cartesi, developers gain access to these decades of meticulously refined operating systems, programming languages, software libraries, and tools, paving the way for the next generation of blockchain applications.  Cartesi empowers Ethereum rollups with real-world software and strong guarantees.  Cartesi designed its own Optimistic Rollups framework embedding its own non-EVM virtual machine based on RISC-V.  Leverage decades‑proven software ecosystems: The Cartesi Machine enables full Linux and RISC‑V stack execution in a composable, verifiable rollup environment.  Cartesi’s architecture is optimized for app‑specific rollups, providing scalable and secure chains tailored to each dApp’s needs, backed by a state-of-the-art fraud proof system, properly categorized as Stage-2 according to L2BEAT.  Token Utility  Governance: CTSI holders can currently stake their tokens to earn rewards and participate in ecosystem governance.   Validator Marketplace: Applications built on Cartesi need validators to monitor and ensure the trustworthiness of transactions. The Validator Marketplace is a decentralized matchmaking service that connects applications with validation service providers. The Validator Marketplace will leverage the CTSI token as a primary means of incentivization in three important ways:  1. Validators will be required to stake CTSI in order to participate, ensuring performance and honest behavior.  2. CTSI holders will be able to delegate their CTSI to experienced validators, allowing tokenholders to share in validation fees without running their own nodes.  3. Token holders can use their CTSI to “buy” a stake in a dApp’s future growth, signaling support for dApps they believe will succeed. The earlier a backer “gets in” on a dApp, the more they are rewarded as that dApp gains traction.  The Validator Marketplace creates a direct link between Cartesi dApp usage and CTSI token demand, enabling token holders to share in the growth and success of the ecosystem.

Cartesi

Cartesi (CTSI) is trending as community members discuss its potential for a breakout, focusing on technical indicators and positive vibes. Some anticipate significant gains and highlight the project's strong fundamentals, including its focus on long-term development. The community is also actively sharing links to Cartesi's Twitter and documentation.

Reefer Token

REEFER Token is trending as discussions revolve around its connection to the cannabis industry, including acceptance at dispensaries and CBD product availability. The community is also actively discussing the token's relaunch, tokenomics adjustments, and partnerships, as well as its listing on various platforms. Some users are also speculating on the potential impact of cannabis legalization on related cryptocurrencies.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention, with community members actively sharing links to Dexscreener and the official website. Some users are drawing comparisons to Bitcoin, while others are highlighting the coin's connection to cannabis culture. There is also discussion around the project trending on UpDog.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending following positive earnings reports, with QNX achieving the Rule of 40. Community members are discussing the undervaluation of the stock, highlighting partnerships with companies like AMD and NVIDIA, and anticipating a potential breakout. Some are pointing to potential manipulation to keep the price suppressed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline 

Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up 

GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?  

KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors. 

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Kymera’s partnerships with Sanofi and Gilead drive value

Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. 

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive. 

Gilead Sciences, Inc. (GILD) said on Wednesday that it entered into an exclusive option and license agreement with biotech company Kymera Therapeutics, Inc. (KYMR) to accelerate the development and commercialization of a class of drugs with potential use in cancer treatment.The drugs belong to a class called molecular glue degrader (MGD), and they target cyclin-dependent kinase 2 (CDK2), a key contributor to tumor growth. CDK2-directed MGDs are a new type of drug designed to remove CDK2 rather than just inhibiting its function.The drugs have a broad oncology treatment potential, including in breast cancer and other solid tumors, the companies said.Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration.Kymera said that it will lead all research activities for the CDK2 program. If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration, the companies said.The transaction is expected to reduce Gilead’s full-year adjusted earnings per share by approximately $0.02 - $0.03. The company in April estimated adjusted and diluted EPS in the range of $7.70 and $8.10 for the full year.Both KYMR and GILD stock are down by 2% on Wednesday morning trading.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KYMR">KYMR</a> is trending in the ‘bearish’ territory, while sentiment around <a href="https://stocktwits.com/symbol/GILD">GILD</a> remained unchanged within ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_9_58_39_AM_png_77702c2682.webp" alt="KYMR's Sentiment Meter and Message Volume as of 9:58 a.m. ET on June 25, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>KYMR's Sentiment Meter and Message Volume as of 9:58 a.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_9_59_13_AM_png_a30db31335.webp" alt="GILD's Sentiment Meter and Message Volume as of 9:59 a.m. ET on June 25, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>GILD's Sentiment Meter and Message Volume as of 9:59 a.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>KYMR shares have risen over 14% this year while GILD soared by about 14%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/ubs-sees-tesla-q2-deliveries-miss-wall-street-estimates/chmJjmARREi">UBS Sees Tesla Q2 Deliveries Miss Wall Street Estimates, But Sees Opportunity For Musk To Focus On Future Of EV Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

Equity

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.


Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$56.79
Prev Close	$56.00
Open	$56.34
Dividend Yield	0.00%
50-Day Moving Average	$45.76
Beta	1.72
Avg. Volume	934,051.52
PE Ratio	-16.66

52-Week High	$59.00
52-Week Low	$19.45
Market Capitalization	$4.14B
EPS (Annual)	-$2.98
Price to Book	4.21
Revenue Per Employee	$250,382.98
Enterprise Value/EBITDA	N/A

KYMR
Kymera Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KYMR News

KYMR Kymera Therapeutics Inc